Heptanoic acid,2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethylester cas no:2746-81-8

NameHeptanoic acid,2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethylester
CAS2746-81-8
SynonymsHeptanoicacid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethylester (7CI,8CI); 1-Piperazineethanol,4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-, heptanoate (ester) (8CI);4-[3-(2-Trifluoromethyl-10-phenothiazinyl)propyl]-1-piperazineethanolenanthate; Fluphenazine enanthate; Moditen enanthate; Prolixin enanthate; SQ16,114; SQ 16144
EINECS(EC#)220-385-0
Molecular FormulaC29H38 F3 N3 O2 S
Molecular Weight549.76

refractive index1.544

Hazardclass6.1(b)

Safety

Poison by intravenous, intramuscular, intraperitoneal, and subcutaneous routes. Human systemic effects by subcutaneous route: muscle weakness; by intramuscular route: musculo-skeletal changes. When Prolixin enanthate (CAS NO.2746-81-8) is heated to decomposition, it emits very toxic fumes of F⁻, SO_x, and NO_x.

RIDADR: 3249
HazardClass: 6.1(b)
PackingGroup: III

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
human	TDLo	intramuscular	1633ug/kg (1.633mg/kg)	MUSCULOSKELETAL: OTHER CHANGES	British Medical Journal. Vol. 2, Pg. 1071, 1966.
human	TDLo	subcutaneous	357ug/kg (0.357mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS	American Journal of Psychiatry. Vol. 119, Pg. 779, 1963.
mouse	LD50	intramuscular	17200ug/kg (17.2mg/kg)		Drugs in Japan Vol. 6, Pg. 701, 1982.
mouse	LD50	intraperitoneal	300mg/kg (300mg/kg)		Drugs in Japan Vol. 6, Pg. 701, 1982.
mouse	LD50	intravenous	56mg/kg (56mg/kg)		U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#03337,
mouse	LD50	oral	41300ug/kg (41.3mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969.
mouse	LD50	subcutaneous	50mg/kg (50mg/kg)		Drugs in Japan Vol. 6, Pg. 701, 1982.
rat	LD50	intraperitoneal	230mg/kg (230mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969.
rat	LD50	oral	230mg/kg (230mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969.
rat	LD50	subcutaneous	475mg/kg (475mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969.
women	TDLo	intramuscular	250ug/kg (0.25mg/kg)	BRAIN AND COVERINGS: CHANGES IN SURFACE EEG BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: COMA	Italian Journal of Neurological Sciences. Vol. 1, Pg. 193, 1980.